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a b s t r a c t
The major active product of ghrelin gene is a 28-amino acid peptide acylated at the serine 3
position with an octanoyl group, called simply ghrelin. Ghrelin has a multiplicity of
physiological functions, affecting GH release, food intake, energy and glucose homeostasis,
gastrointestinal, cardiovascular, pulmonary and immune function, cell proliferation and
differentiation and bone physiology. Nevertheless, recent developments have shown that
ghrelin gene can generate various bioactive molecules besides ghrelin, mainly des-acyl
ghrelin and obestatin, obtained from alternative splicing or from extensive post-transla-
tionalmodification. Although their receptors have not yet been identified, they have already
proven to be active, having intriguingly subtle but opposite physiological actions to ghrelin.
This suggests the existence of a novel endocrine system with multiple effector elements
which not only may have opposite actions but may regulate the action of each other. In this
review, we summarize the steps which lead to the production of the different ghrelin gene
products and examine the most significant differences between them in terms of structure
and actions.
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In 1999, ghrelin was discovered in gastric extracts as a natural
ligand of the orphan growth hormone secretagogue receptor
type 1a (GHS-R1a) [83]. Through this receptor, it acts as a
growth hormone releasing peptide and food intakemodulator
[83]. GHS-R1a is expressed in the hypothalamus and pituitary,
which is consistent with the GH-releasing and appetite-
stimulating effects of ghrelin [72]. However, it has been
demonstrated that GHS-R1a is also expressed in other CNS
areas and peripheral tissues, where ghrelin is also expressed,
suggesting that ghrelin possesses many others effects besides
the release of growth hormone (GH) and the stimulation of
food intake. In fact, numerous studieshave shown that ghrelin
also affects energy and glucose homeostasis, gastrointestinal,
cardiovascular, pulmonary and immune function, cell pro-
liferation and differentiation and bone physiology [84,91,150].
Although the major active product of ghrelin gene is a 28-
amino acid peptide acylated at the serine 3 position with an
octanoyl group (C8:0), called simply ghrelin, recent develop-
ments have shown that ghrelin gene can generate various
bioactive molecules besides ghrelin, mainly des-acyl ghrelin
and obestatin, obtained from alternative splicing or from
extensive post-translational modifications [69,70,75,160,162].
Although their receptors have not yet been identified, they
have already proven to be active, having intriguingly subtle
but opposite physiological actions to ghrelin [84,91,150,162].Fig. 1 – Sequential steps of the production of theThis suggests the existence of a systemwith multiple effector
elements which not only may have opposite actions but may
regulate the action of each other. This knowledge may
facilitate the study of the physiological, pathological and
therapeutic roles of the novel ghrelin system.
In this review, we will summarize the steps which lead to
the production of the different ghrelin gene products and will
examine the most significant differences between them in
terms of structure and actions.2. Ghrelin gene products
2.1. Ghrelin gene
Fig. 1 summarizes the steps which lead to the production of
the different ghrelin gene products.
The human ghrelin gene is located on chromosome 3p25-
26. It comprises five exons and three introns, being the short
first exon only 20 bp long, which encode part of the 50
untranslated region [77,81]. Mature ghrelin (i.e., the 28-amino
acid GH releasing peptide) is encodedby exons 2 and 3with the
remaining proghrelin peptide sequence contained in exons 4
and 5 [75]. The putative initiation codon ATG is located at
nucleotides 34–36, preceded by the consensus initiation
sequence, whereas a terminal codon TAG is found 117 codons
downstream at position 385–387 [75].three major ghrelin gene-derived products.
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appears to require an essential sequence downstream from the
distal initiation site (the noncoding exon 1 region and proximal
region of intron 1) [153]. Additionally,multiple putative binding
sites for transcription factors have been identified including
AP2, basic helix-loop-helix (bHLH), PEA-3, Myb, NF-IL-6,
hepatocyte nuclear factor-5, and NF-B, and half-sites for
estrogen and glucocorticoid response elements [77,81].
2.2. Ghrelin gene-derived transcripts
Two different transcriptional initiation sites have been
described in the ghrelin gene: one at 80 and another at
555 relative to the ATG initiation codon, thus originating two
distinct mRNA transcripts (forms A and B). Human ghrelin
cDNAs studies revealed thatmRNA transcriptA, an alternative
splicing product from exon 2 to exon 4, is the main form of
human ghrelin mRNA in vivo [77].
In rat, mouse and pig, a spliced variant without the codon
for glutamine in position 14 is produced (pre-pro-des-Gln14-
ghrelin mRNA) [69]. Although nearly all of the cDNA clones
isolated from human stomach encoded the pre-pro-ghrelin
mRNA, a few cDNA clones encoded the pre-pro-des-Gln14-
ghrelinmRNA [70]. However, the amount of des-Gln14-ghrelin
from the human stomach and plasma is negligible [70].
As described in detail below, a human exon 3-deleted
mRNA transcript has been described in breast and prostate
cancer [160]. A murine homologue (exon 4-deleted mRNA
transcript) has also been identified in awidely range ofmurine
tissues [75]. It is probable that theses variants, like the pre-pro-
des-Gln14-ghrelin mRNA, are products of the ghrelin gene
produced by alternative splicing mechanisms.
2.3. Ghrelin gene-derived peptides
The described wild-type human ghrelin mRNA (transcript A)
codes for a 117 amino acid long peptide, preproghrelin.
Preproghrelin contains a 23 amino-acid signal peptide and a
94 amino-acid called pro-ghrelin (1–94). This includes the 28
aminoacidmatureghrelin (1–28)anda66aminoacid tail (29–94)
[83,75]. The enzymes responsible for proteolytic cleavage of
preproghrelin to the final products remain largely unknown.
However, recent Western blotting and immunocytochemical
evidences suggest that proghrelin (1–94) can be cleaved by
prohormone convertase 1/3 (PC1/3) inmouse stomach tissue to
generate bona fide ghrelin in vivo [163]. The ghrelin sequence
starts from Gly1, which directly follows the signal peptide, and
the last two residues of ghrelin are Pro27-Arg28, which
correspond to a processing signal [83]. Here, the cleavage most
frequently occurs following the C-terminal Pro27-Arg28, origi-
nating a peptide with 28 amino acids, ghrelin (1–28). Rarely,
Arg28 is removed fromC-terminus of ghrelin (1–28),most likely
byacarboxypeptidaseB-likeenzyme,originatingapeptidewith
27 amino acids, ghrelin (1–27), which terminates in proline [70].
Although ghrelin (1–27) is present only at a very low level in rat
stomach, it is likely 27 and 28 amino acid ghrelinmolecules are
produced through alternative C-terminal processing of the
same ghrelin precursor and that this process may regulate
human ghrelin genematuration. Either ghrelin (1–28) or ghrelin
(1–27) are then subjected to a unique post-translationalmodification: acylation of the hydroxyl group of Ser3. This is
most frequently done with an octanoyl group (C8:0) but may
also be done with decanoyl (C10:0) and possibly decenoyl
moieties (C10:1) [70]. The enzyme responsible for this unique
modification remains unknown, but emerging evidence sug-
gests thatacylation isat leastpartiallydependentuponnutrient
intake. Thus, a recent report showed that acylation of ghrelin
can be increased by ingestion of either medium-chain fatty
acids (MCFAs) ormedium-chain triacylglycerols (MCTs), which
are directly used for the acylation of ghrelin [109]. Nevertheless,
it remains to be determined whether ingested MCTs directly
modulate the Ser3 residue of ghrelin peptide or indirectly
stimulate theacylmodificationofghrelin through the induction
of an acyl-modifying enzyme.
The purification and characterisation of human ghrelin
and analogs from the stomach has been reported and the
collected ghrelins have been classified into two groups on the
basis of amino acid length [ghrelin (1–28) and ghrelin (1–27)]
and into four groups by the type of acylation at Ser3 (non-
acylated, octanoylated, decanoylated, and possibly decenoy-
lated). Although the major active form of human ghrelin is a
twenty-eight-amino acid peptide with an n-octanoyl mod-
ification at Ser3 [ghrelin (1–28)], the ghrelin-derived molecules
observed include decanoyl ghrelin (1–28), decenoyl ghrelin (1–
28), octanoyl ghrelin (1–27) and decanoyl ghrelin-(1–27).
Moreover, all these molecular forms of ghrelin were found
in human plasma as well as in the stomach [70].
Recent evidence suggests that the 66 amino acid tail of wild
type proghrelin (29–94) can circulate as a full-length peptide
(C-ghrelin) or be processed to smaller peptides, mainly
obestatin. Both may have physiological importance.
Pemberton et al. [116] demonstrated the presence of full-
length proghrelin C-terminal peptide (C-ghrelin) in human
plasma that circulate at higher concentrations than mature
octanoyl ghrelin and are elevated in heart failure, suggesting
that itmay be bioactive. More recently, Bang et al. [5] suggested
thatmajorityof tissuestoredandcirculatingC terminal-derived
peptides inmammalsareconsistent inlengthwiththecomplete
C-terminal sequence of proghrelin and respond to metabolic
manipulation, at least in humans, in similar fashion to ghrelin
(1–28). They also demonstrated that the tissue distribution of C-
ghrelinmatches thatofghrelin.Therefore, it isprobable that the
stomach is the main source of circulating C-ghrelin.
In 2005, Zhang et al. [162], by comparative genomic analyses,
proposed the existence of a novel peptide derived from C
terminal of proghrelin. This new peptide has been named
‘obestatin’, based on its appetite-suppressing potential. The
structureofobestatinwasdeducedbyaminoacidsequencingof
a purified 20 residue peptide sequence, combined with mass
spectrometry data, to generate a 23 amino acid sequence
[proghrelin (53–75)]. On the basis of a C-terminal Gly–Lysmotif,
amidation of obestatin was assumed and verified as a
prerequisite for biological activity [162]. Furthermore, themass
spectrometricdata indicated that thispeptidemaybeprocessed
to a 13 amino acid peptide, obestatin (11–23). Further informa-
tion is required to establish exactly how obestatin (11–23) is
formed, although, a recent study indicates that this isoform is
indeed biologically active [62]. Obestatin was originally extra-
cted fromrat stomachandhassubsequentlybeenshowntobea
circulating peptide that may fluctuate in the blood like ghrelin
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obestatin peptides, circulating as distinct entities in thehuman
and rat circulation, or as a secretable hormone in rat tissues [5].
In this study, specific immunoassays directed to the N-
terminus, C-terminus, and mid-region of proghrelin (29–94)
all detected the samemolecular speciesofMr7000, suggesting
that the only forms present were close to the full length 66-
amino acid C-ghrelin [5]. The reason for this is unclear, but
further studies should clarify this issue. Until this happens, we
should assume obestatin as an active peptide, as numerous
recent studies show, even so itmay not exist as an endogenous
peptide.
Pre-pro-des-Gln14-ghrelinmRNA is processed in an almost
similar manner to preproghrelin, the difference being that it
originates a ghrelin peptide devoid of glutamine at position 14,
which has a negligible expression in humans, in contrast to
other species [70].
As noted previously, Yeh et al. reported the expression of a
novel human mRNA transcript designated exon 3-deleted
mRNA transcript in breast and prostate cancer [160]. Amurine
homologue (exon 4-deleted mRNA transcript) has also been
identified in a widely range of tissues [75]. Deletion of exon 3
from the preproghrelin transcript results in a frame shift
which generates, in addition to the mature ghrelin peptide, a
truncated C-peptide with a unique 16-amino-acid peptide tail
(COOH-terminal D3 peptide), which begins with a potential
peptide cleavage site [Arg–Arg]. It remains to be investigated
whether this alternative C-peptide or its potential proteolytic
products circulate in human serum, as does the C-ghrelin
derived from wild-type (full-length) proghrelin. The prelimin-
ary studies indicate that, despite being cleaved from the exon
3-deleted preproghrelin protein, the unique COOH-terminal
D3 peptide (RPQPTSDRPQALLTSL) does not influence cell
proliferation or have any effect on apoptosis when incubated
with prostate cancer cell lines. However, the wide expression
of C-ghrelin suggest that it may possess as-yet-unknown
physiological functions and support the hypothesis that the
generation of the unique C-peptide from the exon 3-deleted
variant of proghrelinmay also have physiological significance.3. Tissue distribution of ghrelin gene-derived
peptides
As stated previously, human ghrelin gene can generate
multiple active molecules by alternative splicing and/or
extensive post-translational modifications. These molecules
can be classified in three main groups: ghrelin and analogs, C-
ghrelin and obestatin. The former group includes octanoyl
ghrelin (1–28), octanoyl ghrelin (1–27), decanoyl ghrelin (1–28),
decanoyl ghrelin (1–27), decenoyl ghrelin (1–28), des-acyl
ghrelin (1–28) and des-acyl ghrelin (1–27). All these molecular
forms of ghrelinwere found in human plasma aswell as in the
stomach, but major active forms seem to be octanoyl ghrelin
(1–28) and des-acyl ghrelin (1–28) [70].
Tissue distribution of ghrelin and des-acyl ghrelin seems to
be similar. In adult mammals, the tissue with the highest
enrichment of ghrelin and des-acyl ghrelin is the stomach
with the next highest amounts found in the duodenum,
jejunum, ileum, cecum, and colon [69]. In the fetus, however,stomach is not the major source of ghrelin because its ghrelin
concentration is very low and only increases after birth. There
is increasing evidence that pancreas and lung are alternative
sources of ghrelin in the fetus. Pancreas begins to express
ghrelin at midgestation and its ghrelin mRNA levels are six to
seven times greater than in the fetal stomach [28]. In pancreas,
total ghrelin concentrations decreases progressively, after
birth, but acylated ghrelin concentrations increases six to
seven times [28]. In their study, Nishi et al. [110] reported that
the amount of acylated ghrelin in murine stomachs increases
gradually during the suckling period to a maximal level at 3
weeks of age and falls sharply after the initiation of weaning.
However, the concentration of total ghrelin, which includes
des-acyl and all acylated forms of ghrelin peptides with intact
C termini in murine stomach, remains unchanged across this
suckling-weaning transition.
In stomach, the cells synthesizing and secreting ghrelin
have been identified as the X/A-cells, which are most
abundant in the fundus [36]. In the human stomach, the
des-acyl:acylated ghrelin ratiowas found to be2:1 [5,70]. This
indicates that just prior to or upon entry to the circulation,
acylated ghrelin is further converted to the nonacylated form,
which constitutes>90% of total circulating ghrelin (see below)
[5,70]. Besides the gastrointestinal tissues, ghrelin is also
expressed, at lower levels, in many other tissues: hypothala-
mus, pituitary, adrenal gland, thyroid, breast, ovary, placenta,
fallopian tube, testis, prostate, liver, gall bladder, pancreas, fat
tissue, human lymphocytes, spleen, kidney, lung, skeletal
muscle, myocardium, vein and skin [55,56]. Ghrelin produced
in tissues other than gastrointestinal tissuesmay have a range
of still-unidentified physiological autocrine or paracrine
effects (since GHS-R1a expression is also detected in many
of these tissues), but endocrine effects are very unlikely.
C-ghrelin is a peptide derived from the carboxyl terminal of
proghrelin (29–94). There may be two types of C-ghrelin: one
derived from the wild type proghrelin and one derived from
the exon 3 (or exon 4)-deleted proghrelin. The former seems to
have the same distribution profile as ghrelin, with highest
concentrations observed in the stomach, followed by the
duodenum and colon [5]. The expression of the second was
detected in prostate cancer cell line lysate, aswell as in human
stomach carcinoma and normal stomach tissue lysates.
Studies related to tissue expression of obestatin are still
limited. Nevertheless, the expression of obestatin was
reported in cells of the gastric mucosa, myenteric plexus
and perinatal pancreas and in Leydig cells of the testis of rats
[29,44,162]. A recent study showed that preproghrelin- and
obestatin-IR cellsweremore numerous than ghrelin-IR cells in
the rat stomach, suggesting the lack of ghrelin in some X/A-
like cells [165]. In the pancreas, obestatin was present in the
peripheral part of the islets, with a distribution distinct from
that of glucagon-producing A cells, insulin-producing beta-
cells, and cells producing pancreatic polypeptide [165].4. Ghrelin gene-derived peptides in
circulation
Two thirds of circulating ghrelin is produced by X/A cells of the
oxyntic mucosa of the stomach and most of the remainder
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radioimmunoassays with different specificities, Patterson
et al. [115] demonstrated that human plasma ghrelin-like
immunoreactivity appears to consist almost completely
(>90%) of des-acyl ghrelin. This is likely due to the shorter
half-life of ghrelin than that of des-acyl ghrelin, as plasma
ghrelin rapidly disappears from the circulation due to the
binding to the GHS-R in the systemic tissues [1]. Deacylation
of ghrelin to des-acyl ghrelin, which rapidly occurs in the
plasma, is also responsible for the reduced half-life of ghrelin
[71].
It is not clear the relationship between the acyl and des-
acyl ghrelin. Both are present in the human plasma, as well
as, in the stomach and both are active, with similar and
opposite actions. There are two theories, not mutually
exclusive: (1) des-acyl ghrelin could result from an incom-
plete acylation of the peptide, with both forms being
secreted via two differently regulated pathways, (2) des-acyl
ghrelin could result from deacylation of ghrelin. In the first
theory, des-acyl ghrelin would be an active peptide produced
directly from ghrelin gene. In the second theory, des-acyl
ghrelin would be produced from ghrelin by deacylation.
Regarding the second theory, numerous enzymes were
proposed to be responsible for this deacylation. It has been
demonstrated that ghrelin is deacylated in human serum by
butyrylcholinesterase and platelet-activating factor acetyl-
hydrolase, while in rat serum only carboxylesterase is
involved [40]. Paraoxonase may also intervene in ghrelin
deacylation, although there is controversy about this issue
[9,40]. Interestingly, these enzymes are associated with
serum lipoproteins, which also participate in the transport
of circulating ghrelin (see below). Lysophospholipase I was
identified as a ghrelin deacylation enzyme in rat stomach
[128]. Importantly, ghrelin deacylation can occur in blood
circulation, as well as, during blood collection and subse-
quent blood handling at room temperature. Therefore, after
collection of blood specimens, EDTA and aprotinin should be
added and the plasma fraction separated by centrifugation
and immediately acidified before freezing at70 8C to ensure
stability of acylated ghrelin during storage [71]. In the future,
we may use esterases inhibitors to ensure ghrelin stability in
human plasma samples.
Various studies suggest that, while des-acyl ghrelin
circulates as a free peptide, the majority of circulating
acylated ghrelin is bound to larger molecules, particularly
lipoproteins [9,40,115]. By reverse phase chromatography
followed by radioimmunoassays, Vriese et al. found
that ghrelin is associated with triglyceride-rich lipoproteins
(TRL), high-density lipoproteins (HDL), very high-
density lipoproteins (VHDL), and to some extent LDL. The
increased hydrophobicity of the acyl side chain of active
ghrelin may cause it to bind to larger plasma proteins in
blood [40].
As stated above, C-ghrelin derived from wild-type ghrelin
was detected in human circulation, and its serum levels were
elevated in patients with heart failure [116]. It remains to be
investigated whether the alternative C-peptide or its potential
proteolytic products from exon 3-deleted preproghrelin
circulate in human serum, as does the C-peptide derived
from wild-type (full-length) proghrelin.5. Factors regulating differential expression of
ghrelin genes products
The factors that regulate the differential expression of ghrelin
gene-derived peptides remain largely undetermined. Never-
theless, some studies have provided some insight regarding
this issue.
Fasting seems not to influence obestatin, while increasing
ghrelin, des-acyl ghrelin and C-ghrelin in the same propor-
tion [5,162]. Feeding also seems to decrease ghrelin, des-acyl
ghrelin and C-ghrelin [5,162]. However, postprandial acylated
ghrelin levels fall more quickly than total ghrelin. This may
reflect changes in secretion of acylated ghrelin and/or the
des-acylation of acylated ghrelin [5]. Effects of feeding on
obestatin plasma levels are controversial with some studies
suggesting no effect and others suggesting a negative effect
[64,5,162].
Chronic positive balance may alter ghrelin:obestatin ratio.
Guo et al. showed that the ratio of pre-prandial ghrelin to
obestatin was higher in obese compared with normal weight
controls even after adjustment for gender and age. Body mass
index was positively correlated with and a significantly
independent determinant of the pre-prandial ghrelin:obesta-
tin ratio [63].
Ingestion of either medium-chain fatty acids (MCFAs) or
medium-chain triacylglycerols (MCTs) increased the stomach
concentrations of acylated ghrelin without changing the total
(acyl- and des-acyl-) ghrelin amounts, suggesting that ghrelin
acylation is at least partially dependent upon nutrient intake
[109].
There may also be a developmental regulation of ghrelin
gene-derived peptides expression. Chanoine et al. showed
that, in plasma, total ghrelin concentrations decreased
abruptly after birth, contrasting with a 3-fold increase in the
concentration of acylated ghrelin [28].
Finally, Yoshimoto et al. [161] suggested that kidneys can
modulate the ratio of the different ghrelin gene-derived
peptides. Des-acyl ghrelin plasma levels, but not ghrelin levels,
were significantly correlated with the serum creatinine level
and were increased 2.8-fold in patients with end-stage renal
disease compared with those in patients with normal renal
function. Bilateral nephrectomy in mice caused marked
increase in the des-acyl ghrelin plasma levels without sig-
nificant changes in the ghrelin levels and ghrelinmRNA level in
thestomach,which is themainsiteofghrelinproduction.These
findings suggest that the kidney is an important site for
clearance and/or degradation of desacyl ghrelin.6. Receptors of ghrelin gene-derived products
The most well investigated ghrelin receptor, GHS-R1, has two
variants resulting from alternative processing of pre-mRNA of
the same gene that are designated type 1a and type 1b [56].
Like GHS-R1a, GHS-R1b has a widespread expression but,
unlike GHS-R1a, does not bind ghrelin or synthetic GHS and it
is not clear whether it is functional [56].
GHS-R1a is highly expressed in the hypothalamus and
pituitary, consistent with ghrelin’s observed action on the
pituitary, and its role in the control of appetite, food intake and
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sion has also been reported in areas of the CNS that affect
biological rhythms, mood, cognition, memory, and learning,
such as the hippocampus, pars compacta of the substancia
nigra, ventral tegmental area, dorsal and medial raphe´ nuclei
and Edinger–Westphal nucleus and pyriform cortex [62].
Moreover, a ghrelin-receptor transcript product is also found
in the vagal nodose ganglion, whose activation may mediate
many ghrelin effects [17] andmultiple peripheral organs, such
as the stomach, intestine, pancreas, thyroid, gonads, adrenal,
kidney, heart and vasculature, bone, various tumors and cells
lines express GHS-R1a [56,91]. These data are in agreement
with the rising spectrum of actions of ghrelin. Recent
experiments performed in GHS-R1a knockout mice showed
that GHS-R1a is essential for the stimulatory effects of ghrelin
on GH secretion, as well as, its orexigenic effects [135].
Acylation at Ser3 is essential for GHS-R1a activation [11,100].
All acyl-modified ghrelin analogs seem to have the same
potency to induce an increase of Ca2+ concentration in the
GHS-R-expressing cells and to stimulate GH release in
anaesthetised rats [70]. In addition, short peptides encom-
passing the first four or five residues of ghrelin were found to
functionally activate GHS-R about as efficiently as the full
length ghrelin and only the segment Gly-Ser-Ser-(n-octanoyl)-
Phe appeared to constitute the ‘active core’ required for
agonist potency at human GHS-R [11].
Many studies have demonstrated that ghrelin binds and is
active on some cells lines devoid of GHS-R1a and that ghrelin
and other GHS show different binding and activities in the
same system, reinforcing the idea that GHS-R1a is not the sole
receptor for ghrelin and/or GHS. Based on binding and
functional studies, the list is continuously growing and
actually includes receptors for des-acyl ghrelin, receptors
other than GHS-R1a for ghrelin, common receptors for ghrelin
and des-acyl ghrelin with the same or antagonistic effects in
response to these two ligands and even receptors with specific
binding for peptidyl GHSs (hexarelin) [18]. Only the last one
has been characterized. In the coronary vasculature, this
receptor has been identified as CD36, a multifunctional B-type
scavenger receptor [12].
Des-acyl ghrelin does not bind GHS-R1a, as acylation at
Ser3 is essential for GHS-1a activation. Therefore, its effects
should be mediated by other receptors. As noted above, there
may be receptors specific for des-acyl ghrelin and receptors
common to acyl and des-acyl ghrelin, although, none of these
have been characterized yet. Several recent in vitro studies
have shown that des-acyl ghrelin exhibits biological activities
on cell proliferation and metabolism and binds to cell
membranes of cardiomyocytes, adipocytes, prostatic and
skeletal muscle cells [4,24,48,104].
Obestatin was initially reported to be the endogenous
ligand of the orphan receptor G protein-coupled receptor 39
(GPR39), a GTP-binding protein-coupled receptor that shares
homology with GHS-R1a [162]. However, recent reports
indicate that obestatin is unlikely to be the endogenous
ligand for GPR39 based on the lack of specific binding on
GRP39 receptor expressing cells and the absence of signal
transduction pathway activation [30,89]. In contrast, the
potency and efficacy of Zn2+ in activating signalling pathways
indicates that this metal ion could be a physiologicallyrelevant agonist or modulator of GPR39 [68]. Thus, we still
wait for the identification of the obestatin receptor(s).7. Effects of ghrelin gene-derived products
7.1. GH secretion
Table 1 summarizes the differences between physiological
actions of ghrelin, des-acyl ghrelin and obestatin.
Ghrelin possesses a strong and dose-related GH-releasing
effect, both in vitro and in vivo, in humans and animals [97].
The ghrelin GH-releasing effect seems to result from ghrelin
binding toGHSR-1a on somatotrophic cells at the pituitary [97],
ghrelin-induced activation of GHRH-neurons and inhibition of
somatostatin neurons at the hypothalamus [119] and ghrelin-
induced vagal afferent activation [17].
Under normal situations des-acyl ghrelin does not influ-
ence GH secretion, as it cannot bind GHS-R1a. However, in
transgenic mice over expressing des-acyl ghrelin, it may
modulate the GH-IGF-I axis (reducing responses of GH to
administered ghrelin) and results in a small phenotype in
transgenic mice [2].
Most studies showed that neither intravenous nor intra-
cerebroventricular administration of obestatin affects the
secretion of GH in rats [13,111,125,158,162]. Nevertheless, a
recent study showed that obestatin, in some conditions, can
inhibit exogenous ghrelin action on GH release [164]. It
remains to be determined whether obestatin modulates
endogenous ghrelin actions.
7.2. Appetite and body weight
Several studies have shown that ghrelin regulates appetite
and body weight. Short-term fasting results in pre-prandial
rise in ghrelin levels and hunger scores corresponded to
ghrelin levels in a study involving subjects initiating meals
voluntarily without time- and food-related clues [35]. This
implicates that ghrelin might be an important factor for
meal initiation as, in animals and humans, infusion of
ghrelin stimulates appetite and increases spontaneous food
intake [90,156]. Recent studies have clarified the cellular
mechanism underlying the orexigenic effect of ghrelin. By
activating vagal afferents [155] or via the bloodstream [67],
the signal reaches the arcuate nucleus of the hypothalamus.
Here, neurones containing the orexigenic peptides neuro-
peptide Y and agouti related peptide are activated, while
neurones containing the anorexigenic peptides cocaine and
amphetamine related transcript and pro-opiomelanocortin
are inhibited [31]. The arcuate neurones project to other
nuclei, among them orexin containing neurones in the
lateral hypothalamic area, to stimulate appetite [146].
Recent data show that central ghrelin (ghrelin secreted by
hypothalamic neurones) could be of importance in the
orexigenic effect of ghrelin [34].
Beyond an orexigenic effect, ghrelin can also regulate body
weight in long-term. Ghrelin responds to changes in body
weight: levels of ghrelin increase after weight loss and go
down after weight gain [35]. Long-term ghrelin administration
promotesweight gain, not only by stimulating food intake, but
Table 1 – Effects of ghrelin gene-derived products
Effect Ghrelin Des-acyl ghrelin Obestatin
Endocrine
GH " $# $#
ACTH, TSH, AVP " $ $
Appetite/body weight " #" #$
Water intake # $ #
Metabolism
Glucose
Glucose sensing # nd nd
Insulin secretion #" # #"$
Insulin action " (periphery)/# (liver) $ (periphery)/# (liver) nd
Glucose production " # nd
Lipid content
Liver " nd nd
Muscle # nd nd
Adipocyte " " nd
Reproduction
LH secretion # # nd
Embryogenesis # nd nd
Testosterone secretion # nd nd
Spermatogenesis # nd nd
Follicle survival and action " nd "
Gastrointestinal
Exocrine secretion "#$ (stomach)/" (pancreas) $ (stomach) " (pancreas)
Epithelial protection " nd nd
Motility " (stomach and colon) # (stomach)/$ (jejune) # (stomach and jejune)/$
Cardiovascular
Vascular dymanics
Macrovessels dilation " (systemic)/# (coronary) " (systemic) nd
Microvessels dilation " nd nd
Endothelium function " nd nd
Heart function " " $
Cell proliferation "# "# "
Imune function
Immune cell production " $ nd
Cytokine production # $ nd
Neutrophil action # nd nd
Bone
Osteoblast production " " $
Osteoblast action " nd $
Sleep " $ "
Memory " $ "
Anxiety " $ #
Iris muscle relaxation
Sphincter " " nd
Dilator " $ nd
("), stimulation; (#), inhibition; ($), no effect; nd, effect not determined.
p e p t i d e s 2 9 ( 2 0 0 8 ) 1 2 5 5 – 1 2 7 0 1261also by regulating other aspects of energy homeostasis.
Indeed, ghrelin increases the preference for dietary fat [129]
and directly promotes adipogenesis [144]. It can also decrease
lipolysis [104], adipocyte apoptosis [76], energy expenditure
and sympathetic nervous system activity [159], body tem-perature [148], proinflammatory cytokine production [41] and
locomotor activity [141].
Depending upon the experimental condition, des-acyl
ghrelin has been reported to be able to either inhibit [3,32,99]
or stimulate [147] food intake.Nevertheless,mostavailabledata
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food intake. The food-inhibiting effect seems to be specific for
central administration and mediated by increased gene
expression of cocaine and amphetamine regulated transcript
and urocortin on the paraventricular nucleus and the arcuate
nucleus in the hypothalamus [3]. In addition, des-acyl ghrelin
over expressing mice exhibited a decrease in body weight and
fat pad mass weight accompanied by moderately decreased
linear growth, suggesting that, in contrast to ghrelin, des-acyl
ghrelin generates a negative energy balance [3].
There is great controversy about the effects of obestatin on
food intake with some studies suggesting that it may inhibit
food intake and suppress body weight under basal and
ghrelin-stimulated conditions [13,61,86,162,164] and others
suggesting no effect [58,111,127,131]. Recent studies have
partially clarified this issue. In one of these studies, intraper-
itoneal obestatin suppressed food intake and bodyweight gain
in rodent in an U-shaped dose–response relationship. This
relationship may explain the difficulties in reproducing the
effects of obestatin on feeding reported by some groups [86]. In
the other study, intracerebroventricular administration of
obestatin inhibited water drinking in ad libitum-fed and -
watered rats, and in food- and water-deprived animals [125].
The effects on water drinking preceded and were more
pronounced than any effect on food intake, and did not
appear to be the result of altered locomotor/behavioral
activity. Thus, it appears that obestatin possess biologic
activity but that the effect on food intake may be secondary
to an initial action in inhibiting thirst phenomenon referred to
by some authors as dehydration anorexia [125]. Interestingly,
ghrelin also seems to have an antidipsinogenic effect.
Intracerebroventricular injection of ghrelin inhibited water
intake in chicks under both ad libitumand17-hwater deprived
drinking conditions. On the other hand, des-acyl ghrelin does
not reduce water intake [138].
7.3. Metabolism
7.3.1. Glucose metabolism
Ghrelin has been implicated in the regulation of glucose
homeostasis, by modulating sensitivity of glucose-sensing
neurones in the brain, insulin secretion and action andhepatic
glucose production. Recently, it was demonstrated that
ghrelin can inhibit the activity of the glucosensing neurons
(glucose-inhibited and glucose- excited neurons) in the dorsal
vagal complex of rats [118,152]. Depending upon the experi-
mental condition, ghrelin has been reported to be able to
either inhibit or stimulate insulin secretion in animals and
humans [14]. Nevertheless, most available data suggest a
negative association between systemic ghrelin and insulin
levels, with ghrelin inhibiting insulin secretion both in vitro
and in most human or animal studies [14]. This effect may be
mediated by GHS-R1a whose expression was detected in
animal and human endocrine pancreas [56]. In addition,
ghrelin may also regulate some peripheral effects of insulin.
Thus, ghrelin hampers insulin’s capacity to suppress endo-
genous glucose production, whereas it reinforces the action of
insulin on glucose disposal in mice [66], inhibits secretion of
the insulin-sensitizing protein adiponectin from adipocytes
[112] and stimulates secretion of the counter-regulatoryhormones, including GH, cortisol and epinephrine [97] and
possibly glucagon [124].
Acute ghrelin administration in humans increases plasma
glucose levels [14]. The hyperglycaemic effect of ghrelin may
result not only from the endocrine effects of ghrelin, but also
from ghrelin’s direct effects on hepatocytes, where it has
already been shown to be able tomodulate glycogen synthesis
and gluconeogenesis, stimulating hepatic glucose production
[52,105].
Des-acyl ghrelin can also regulate glucose metabolism.
Recently, it was demonstrated that at a ten times higher
concentration than acyl ghrelin (corresponding to the ratio of
the two peptides in circulation), des-acyl ghrelin abolished the
effects of acyl ghrelin on insulin secretion frommouse and rat
pancreas isolated islets [120]. In addition, it hampers insulin’s
capacity to inhibit endogenous glucose production, but does
not affect glucose disposal. The restraining effects of des-acyl
ghrelin and ghrelin on hepatic insulin action are abolished by
simultaneous administration of both peptides [66,114]. Finally,
des-acyl ghrelin inhibits glucose output by primary hepato-
cytes and counteracts the stimulatory effect of ghrelin on
glucose release. These actionsmust bemediated by a receptor
other thanGHS-R1a, and apparently,wemust consider ghrelin
and des-acyl ghrelin as separate hormones that can modify
each other actions on glucose handling [52].
Data regarding effects of obestatin on insulin secretion are
limited and controversial as stimulation [60], inhibition [120],
and lack of effect [61] have been reported. Further studies are
necessary to clarify this issue and the effects of obestatin on
glucose-sensing neurones, insulin action and hepatic glucose
production.
7.3.2. Lipid metabolism
Ghrelin has also been implicated on the regulation of lipid
metabolism, with effects in the liver, skeletal muscle and
adipose tissue. In the liver, ghrelin induced lipogenic patterns
of gene expression and triglyceride content, whereas the
activity of the stimulator of fatty acid oxidation, AMPK, was
reduced [6]. In the gastrocnemius muscle, ghrelin reduced
triglyceride content, increased mitochondrial oxidative
enzyme activities and increased mRNA encoding uncoupling
protein 2, independent of changes in expression of fat
metabolism genes and phosphorylation of AMPK [6]. Peroxi-
some proliferator activated receptor g, which, upon activation,
reduces muscle fat content, was also selectively increased in
skeletal muscle [6]. Thus, ghrelin favours triglyceride deposi-
tion in the liver over the skeletal muscle. Moreover, ghrelin
also acts directly on adipocytes. Ghrelin stimulates lipogenesis
in differentiated adipocytes in vitro and in vivo, by increasing
the levels of peroxisome proliferator-activated receptor a and
the insulin-induced glucose uptake [114,144], antagonizes
lipolysis, reducing isoproterenol-stimulated lipolysis in vitro
[104] and stimulates the proliferation and differentiation of
preadipocytes [76].
Data regarding effects of des-acyl ghrelin on lipid meta-
bolism are scarce. Similar to acyl ghrelin, des-acyl ghrelin
promotes lipogenesis directly in vivo [144] and inhibits
isoproterenol-induced lipolysis in rat adipocytes [104] by a
mechanism independent of GHS-R1a. The effects of obestatin
on lipid metabolism have not yet been determined.
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To date, expression of ghrelin and its receptor have been
documented in various reproductive organs, such as placenta,
testis Leydig cells, rat ovary, mouse embryo and endome-
trium, suggesting that ghrelin may have a role on the
regulation of reproductive function [20,53,54,80,142]. Indeed,
available data suggest that ghrelin regulates several aspects of
reproductive physiology, at least partially, in a paracrine-
autocrine manner.
At the pituitary, ghrelin suppress different aspects of
pulsatile LH secretion, in animals and in healthy humans,
both in vivo and in vitro conditions [47,88]. Of note, ghrelin is
also able to decrease GnRH release ex vivo by hypothalamic
explants from ovariectomized female rats and decreases
GnRH-induced LH release ex vivo by pituitaries from
prepubertal animals and adult cyclic female rats, at different
stages of the estrous cycle [47]. This observation, together
with its reported effects on LH pulsatilty, strongly suggests a
major central (hypothalamic) site of action for the inhibitory
effects of ghrelin on the gonadotropic axis. Noteworthy, the
actions of ghrelin on FSH secretion in vivo remain less well
characterized.
Besides central actions on the reproductive axis, several
lines of evidence indicate that ghrelin is also expressed and
conducts specific biological effects directly at the gonadal
level; a phenomenon which illustrates the multifaceted mode
of action of ghrelin in the control of the gonadotropic axis.
An isolated study showed that, in cultured whole porcine
follicles, treatment with ghrelin resulted in an increase in
estradiol secretion, aromatase activity and a decrease in
caspase-3 activity [121]. In males, ghrelin has an inhibitory
role, decreasing the expression of the stem cell factor (SCF)
gene, a key mediator of spermatogenesis and a putative
regulator of Leydig cell development [7] and inhibitor of hCG-
and cAMP-stimulated testosterone secretion in vitro [142].
Ghrelin may also regulate preimplantation embryo during
its development. Addition of ghrelin to culture media inhibits
the development of mouse preimplantation embryos [80].
Recently, itwas demonstrated that ghrelin exerts an inhibitory
effect on contractility of dissected myometrial strips sus-
pended under isometric conditions, undergoing spontaneous
and oxytocin-induced contractions [65]. Overall, these find-
ings show a predominantly inhibitory role of ghrelin in
reproductive function.
Concerning des-acyl ghrelin, a recent study involving acute
administration to adult male rats in freely moving conditions,
aswell aschronic infusions,demonstrated thatdes-acyl ghrelin
is able tomimic the inhibitory effects of acylated ghrelin on LH
secretion [98]. Likewise, repeated administration of des-acyl
ghrelinwas as effective as acylated ghrelin in inducing a partial
suppression of the activation of the gonadotropic axis at
puberty, as evidenced by similar decreases in serum LH levels
and percentages of balanopreputial separation in ghrelin-
treated groups [98].
Data regarding obestatin effects on reproductive function
are very limited. A recent study demonstrated that obestatin
maydirectly control porcine ovarian granulosa cells functions,
stimulating proliferation and apoptosis of theses cells and the
secretion of progesterone [102].7.5. Gastrointestinal function
Available data suggest that ghrelin affects many aspects of GI
function, including exocrine secretion, epithelial protection
and motility.
Results regarding the effects of ghrelin on gastric acid
secretion are equivocal, as stimulation (probably via vagal
pathways stimulating parietal cells) [157], inhibition [131], and
lack of effect [43] have been reported. It was suggested that
conflicting data may reflect the presence of both stimulatory
and inhibitory pathways, and that experimental conditions
and models may determine how they balance out. The
stimulatory action of ghrelin on gastric secretion may be
important in preparing the stomach to process food. Ghrelin is
also able to stimulate pancreatic protein secretion via central
pathways [94].
Ghrelinmayalso stimulate cell proliferationanddifferentia-
tion of the gastrointestinal epithelium. Indeed, a gastroprotec-
tive effect has been demonstrated in various models, which
seems to depend mainly on vagal activity, sensory nerves and
hyperaemia mediated by nitric oxide synthase–nitric oxide
(NOS–NO) and cyclooxygenase–prostaglandin systems [15,16].
The protective effect has also been demonstrated in experi-
mental colitis [57]. A recent study showed that, both intraper-
itoneally and centrally administered, ghrelin suppresses
mucosal intestinal apoptosis in fasting rats [113].
Structural relationships between ghrelin and motilin, lead
to evaluation of the motility effects of ghrelin. Indeed, it was
demonstrated that ghrelin, likemotilin, induces themigrating
motor complex (MMC) and accelerates gastric emptying, both
in humans and rodents [139,140]. Also, ghrelin seems to
accelerate colonic motility [130]. Prokinetic actions of ghrelin
are mediated by the cholinergic system, via central mechan-
isms and probably by the myenteric plexus [38,50].
Des-acyl ghrelin does not seem to influence gastric
secretion [43,132]. Regarding to motility, des-acyl ghrelin
inhibits gastric emptying without altering small intestinal
transit [3,32]. Peripheral des-acyl ghrelin may induce this
function by direct activation of brain receptor (CRF 2) by
crossing the blood-brain barrier but not by the activation of
vagal afferent pathways [32]. The effects on cell proliferation
and differentiation of the gastrointestinal epitheliumwere not
yet determined.
Recently, obestatin was demonstrated to stimulate the
secretion of pancreatic juice enzymes through a vagal
pathway in anaesthetized rats [78]. As with the effects of
obestatin on regulation of food intake, its effects on
gastrointestinal motility are involved in great controversy
with most studies reporting no effect [8,39,58] and others
reporting a negative effect (in gastric and jejunal motility)
under basal and ghrelin-stimulated conditions [162]. Further
studies should clarify this issue and its effects on gastric
exocrine secretion and epithelial protection.
7.6. Cardiovascular function
Numerous studies suggest that ghrelin has a wide array of
cardiovascular activities.
Regarding the macrocirculation, the vasoactive effects of
ghrelin depend on the vascular territory. In the systemic
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lium-independent [82,149] and involves peripheral and central
mechanisms [95]. Indeed, intravenous administration of
ghrelin in humans causes a significant decrease in mean
arterial pressure, but does not change heart rate [106]. By
contrast, ghrelin increases coronary perfusion pressure in rat
hearts perfused using the Langendorf systemand significantly
increases pressure-induced myogenic tone in coronary arter-
ioles [117]. In the microcirculation, ghrelin increases vascular
flow, and this action may affect other physiological functions
of ghrelin [145].
Ghrelin is also able to improve endothelial function by
inhibiting basal and TNF-a-induced chemotactic cytokine
production, increasing nitric oxide bioactivity and inhibiting
angiotensin II-induced migration of human aortic endothelial
cells [93,123,143].
Salutary cardiotropic effects of ghrelin have been demon-
strated in various experimental models. These may result not
only from an increase in GH, appetite and vasodilation, and
decrease in cytokine production, but also from direct effects of
ghrelin on cardiomyocytes. In vitro, ghrelin decreases inotrop-
ism [10,133] and lusitropism [133], inhibits apoptosis of
cardiomyocytes [4], improves myocardial function during
ischemia/reperfusion and isoproterenol-induced injury [27,92]
and reduces infarct size [49]. In healthy volunteers [106] and
patients with chronic heart failure [107], ghrelin decreases
systemicvascular resistance,which results in increasedcardiac
output as shown by increased cardiac index and stroke-volume
index.
Compared with ghrelin, des-acyl ghrelin shows similar
endothelium independent vasodilator potency [82,149]. Like
ghrelin, des-acyl ghrelin decreases inotropism [10], inhibits
apoptosis of cardiomyocytes [4] and has cardioprotective
effects on myocardial injury induced by isoproterenol in rats
[92].
An isolated study found no effect of obestatin on cardio-
myocyte viability and metabolism [73]. Additional studies are
needed to evaluated effects of obestatin on vascular and
endothelial functions.
7.7. Cellular proliferation
Recent evidence supports a role for ghrelin in the regulation of
proliferation, apoptosis and differentiation of various normal
and neoplastic cells lines, via mechanisms dependent and
independent of GHS-R1a. Ghrelin stimulates the proliferation
and inhibits apoptosis of the H9c2 cardiomyocyte cell line [4],
human adrenal zona glomerulosa cells [101], preadipocytes
[76], osteoblastic cells [96] and pancreatic beta-cells [59] and
rat fetal spinal cord [126] and skin cells [108]. Thus, peripheral
actions of ghrelin result not only frommodulation of function,
but also from regulation of survival/proliferation of target
cells. Additionally, ghrelin stimulates differentiation of osteo-
blastic cells [96] and C2C12 skeletal myoblasts [48].
Evidence that ghrelin and ghrelin/GHS receptors are coex-
pressedinseveral tumorsandrelatedcell linessuggests that the
ghrelin system is likely to play an important autocrine/
paracrine role in neoplasms development.
In vitro experiments demonstrated that ghrelin may
stimulate or inhibit the proliferation of several human tumorcell lines. An antiproliferative effect of ghrelin was shown
in small cell [25], breast [23], thyroid [151] and prostate
carcinoma cell lines [24], while a proliferative effect was
shown in hepatoma [105], prostatic carcinoma [74] and
pancreatic carcinoma cell lines [45]. Additionally, ghrelin
may also regulate neoplasm proliferation by exerting an
inhibitory effect on angiogenic factors. In assays developed
with endothelial cells (HUVEC cells), ghrelin inhibited FGF-2-
induced cell proliferation, as well as, Matrigel tube formation
[33].
Des-acyl ghrelin shares with ghrelin many effects on
regulation of cell proliferation, apoptosis and differentiation.
Des-acyl promotes cell survival and inhibits apoptosis of H9c2
cardiomyocyte cell line [4] and in pancreatic beta-cells [59]. In
vitro, des-acyl ghrelin induces proliferation of rat fetal spinal
cord [126] and skin cells [108]. Moreover, des-acyl ghrelin
promotes differentiation and fusion of C2C12 skeletal myo-
blasts [48]. Like ghrelin, des-acyl ghrelin inhibits proliferation
and increases apoptosis of small cell carcinoma cell lines [25]
and exerts different effects on cell proliferation in prostate
carcinoma cell lines [24].
Obestatin may also be able to influence cell proliferation
and apoptosis. It was demonstrated that obestatin induces cell
proliferation in primary cultures of human retinal epithelial
cells by MEK/ERK 1/2 phosphorylation [19] and promotes
human islets cells survival through cAMP increase and
involvement of AC/cAMP/PKA signalling [60].
7.8. Immunomodulation
GHSR mRNA is expressed in several lymphoid organs [56] and
in various leukocyte subsets including T and B cells, mono-
cytes [41], suggesting that ghrelin might play some role in the
generation and/or control of immune interactions. In fact,
various studies demonstrated that ghrelin may modulate
immune cell proliferation and activation and secretion of
proinflamatory cytokines.
Chronic administration of a ghrelin mimetic to old mice
stimulated growth, differentiation and cellularity of the
thymus, in addition to increasing T-cell production [85]. This
resulted in an enhanced resistance to the initiation of
neoplasms and subsequent metastasis in animals inoculated
with lymphoma cells and an improved thymic engraftment in
bone marrow transplant recipients [85].
In vitro studies showed that ghrelin inhibited ROS
generation by human PMN in a dose-dependent manner
[46]. Interestingly, ghrelin ameliorates pancreaticobiliary
inflammation and associated remote organ injury induced
by pancreaticobiliary obstruction, by inhibiting neutrophil
action [79].
Ghrelin alsomodulates the production of proinflammatory
cytokines. Recently, it has been shown that ghrelin and the
GHS-R are found in human T cells and monocytes, where
ghrelin specifically inhibited chronic, LPS- and leptin-induced
synthesis of proinflammatory anorectic cytokines such as
leptin, interleukin 1b (IL-1b), IL-6 and tumor necrosis factor a
(TNF-a) [26,41,93]. These data have established a novel role for
ghrelin in immune cell function as a negative regulator of
inflammatory cytokine expression induced by cell activation
by antigen, mitogens, or leptin.
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function [42,93], while effects of obestatin on immune system
were not yet determined.
7.9. Bone physiology
Recent studies indicate that ghrelin is also involved in the
regulation of bone growth and metabolism as one of its
peripheral effects. It has been demonstrated that primary
osteoblasts, aswell as osteoblastic cell lines of various species,
express GHS-R1a [96]. Evidence was also provided that ghrelin
treatment directly stimulates fetal rat calvarial osteoblastic
cells proliferation and differentiation, alkaline phosphatase
activity and calcium accumulation in the matrix primary [96].
In addition, ghrelin increased bone mineral density of both
normal and GH-deficient rats [51]. These observations show
that ghrelin directly stimulates bone formation.
Data regarding effects of des-acyl ghrelin and obestatin on
bone physiology are very limited. A recent study demon-
strated des-acyl ghrelin stimulates human osteoblasts pro-
liferation in the absence of GHS-R1a [37]. Unlike ghrelin,
obestatin does not exert any relevant activity in chondrocytes
[87].
7.10. Other effects
Numerous other effects have been attributed to ghrelin. The
continuously increasing list includes stimulation of prolactin,
ACTH, AVP [103,106], promotion of slow-wave sleep [154],
memory retention and anxiety-like behavior [21] and stimula-
tion of milk secretion [108]. Recently, we have reported that
ghrelin is expressed in the iris and induces relaxation of iris
sphincter and dilator muscles [122].
Des-acyl ghrelin does not influence sleep, memory,
behavior nor milk secretion [21,108,154]. Relaxing effects of
des-acyl ghrelin in iris sphincter muscle were similar to those
of ghrelin, while in dilator muscle, des-acyl ghrelin did not
significantly alter active tension and the relaxing effect of
ghrelin was blunted by GHSR-1a blockage [122].
Neither intravenous nor intracerebroventricular adminis-
tration of obestatin affects the secretion of prolactin, TSH and
ACTH in rats [13,111,125,158,162]. On the other hand, a recent
report provides evidence indicating that obestatin effects are
functionally opposite on anxiety to that of ghrelin, while both
these related peptides increase memory retention [22].
Recently, it was demonstrated that obestatin has also a
sleep-promoting effect when administrated centrally but not
peripherally [137].8. Ghrelin and GHS-R knockout mice
Recently, ghrelin (ghrelin/) and GHS-R (GHS-R/) knock-
out adult mice were generated to study the importance of
GHS-R to ghrelin actions and the biologically relevant actions
of the ghrelin/GHS-R system [134,135,136]. GHS-R/mice are
refractory to the stimulatory effects of ghrelin on GH release
and appetite, confirming that the GHS-R is a physiologically
relevant ghrelin receptor. Additionally, comparisons have
revealed no major phenotypic differences and only modestdifferences between ghrelin/ or GHS-R/ mice and wild
type mice. Deletions of ghrelin or the GHS-R impairs neither
growth nor appetite. Moreover, deletion of ghrelin or the GHS-
R in these adult mice does not prevent diet-induced obesity or
prevent weight gain after weight loss. On the other hand,
under caloric restriction, theweight loss of ghrelin/ or GHS-
R/ mice was identical to wild type mice, but blood glucose
levels were significantly lower. Ablation of ghrelin in mice
increased glucose-induced insulin secretion, and improved
peripheral insulin sensitivity, suggesting that adult congenic
ghrelin/ and GHS-R/ mice are not resistant to diet-
induced obesity, but under conditions of negative energy
balance show impairment in maintaining glucose home-
ostasis. These results support the hypothesis that the primary
function of ghrelin in adult mice is to modulate glucose
sensing and insulin sensitivity, rather than directly regulate
energy intake and energy expenditure. Nevertheless, although
ghrelin or GHS-R1a knockout animals have a similar appear-
ance to wild type animals, suggesting that ghrelin does not
play a significant role in determining growth or appetite, the
presence of compensatorymechanisms cannot be ruled out as
an explanation for these findings.9. Conclusion
Since its discovery in 1999, there has been a tremendous
interest on ghrelin, so that it has become one of the most
important subjects of scientific research. This is due to the
ubiquity of ghrelin and receptors of ghrelin and the multi-
plicity of physiological functions of ghrelin. Current evidence
shows ghrelin affects GH release, food intake, energy and
glucose homeostasis, gastrointestinal, cardiovascular, pul-
monary and immune function, cell proliferation and differ-
entiation and bone physiology. The discovery of des-acyl
ghrelin and obestatin as bioactive products of the ghrelin gene,
produced by alternative splicing or extensive post-transla-
tional modifications, brought even more attention to this
novel endocrine system. Des-acyl ghrelin and obestatin have
already proven to be active, influencing many of the
physiological functions modulated by ghrelin, with similar
and opposite effects. Thus ghrelin, des-acyl ghrelin and
obestatin may be part of a system with multiple effector
elements, which not only may have opposite actions but may
regulate the action of each other. Nonetheless, many ques-
tions remain unsolved:1. Is obestatin an endogenous peptidewith biological activity?
And if it is active, what are its receptors?2. Is C-ghrelin a distinct peptide with biological activity? And
if it is active, what are its receptors?3. Which is the relation between acylated and non-acylated
forms of ghrelin?4. What are the receptors of des-acyl ghrelin?5. How is the differential expression of ghrelin gene products
regulated?6. What are the enzymes responsible for preproghrelin
processing?7. What are the enzymes responsible for acylation/deacyla-
tion of ghrelin? How is this process regulated?
p e p t i d e s 2 9 ( 2 0 0 8 ) 1 2 5 5 – 1 2 7 012668. What are the differences between physiological and phar-
macological actions of ghrelin?
These questions should be answered in the near future.
The answers will help us to better understand the physiolo-
gical, pathological and therapeutic roles of this novel endo-
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